Amgen Complaint Against Roche Accepted By ITC
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. International Trade Commission has agreed to review Amgen's complaint against Roche regarding Roche's importation of pegylated recombinant human erythropoietin, Amgen announced May 9
You may also be interested in...
Amgen’s ITC Complaint Against Roche’s Peg-EPO Dismissed
U.S. International Trade Commission ruling finds that Roche’s CERA is subject to a clinical trial exemption from patent infringement.
Amgen’s ITC Complaint Against Roche’s Peg-EPO Dismissed
U.S. International Trade Commission ruling finds that Roche’s CERA is subject to a clinical trial exemption from patent infringement.
Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks
CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.